Get the Stockscreener App
0.237
13.61%
0.0284
After Hours:
.21
-0.027
-11.39%
Calidi Biotherapeutics Inc stock is traded at $0.237, with a volume of 3.56M.
It is up +13.61% in the last 24 hours and down -0.75% over the past month.
Calidi Biotherapeutics Inc., a clinical stage immuno-oncology company, engages in developing immunotherapies for the treatment of cancer. It engages in advancing a potent allogeneic stem cell capable of carrying an anti-tumor payload for use in multiple oncology indications, including high-grade gliomas and solid tumors. The company's cell-based delivery platforms are designed to protect, amplify, and potentiate oncolytic viruses leading to enhanced efficacy and improved patient safety. Its pipeline of products candidates in the clinic includes NeuroNova that are allogeneic neural stem cells loaded with an oncolytic adenovirus for the treatment of high-grade gliomas; and SuperNova, which are allogeneic adipose-derived mesenchymal stem cells loaded with tumor-selective CAL1 oncolytic vaccinia virus for the treatment of advanced metastatic solid tumors. The company was founded in 2014 and is headquartered in San Diego, California.
See More
Previous Close:
$0.2086
Open:
$0.2113
24h Volume:
3.56M
Relative Volume:
1.09
Market Cap:
$2.58M
Revenue:
-
Net Income/Loss:
$-25.74M
P/E Ratio:
-0.048
EPS:
-4.938
Net Cash Flow:
$-21.41M
1W Performance:
+7.73%
1M Performance:
-0.75%
6M Performance:
-84.61%
1Y Performance:
-95.91%
1-Day Range:
$0.1985
$0.237
1-Week Range:
$0.1914
$0.267
52-Week Range:
$0.1914
$19.20
Calidi Biotherapeutics Inc Stock (CLDI) Company Profile
Name
Calidi Biotherapeutics Inc
Sector
Industry
Phone
(858) 794-9600
Address
4475 Executive Drive, Suite 200, San Diego
Compare CLDI vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CLDI
Calidi Biotherapeutics Inc
|
0.237 | 2.44M | 0 | -25.74M | -21.41M | -4.938 |
VRTX
Vertex Pharmaceuticals Inc
|
427.38 | 109.41B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
707.06 | 76.72B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
781.72 | 48.20B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
309.49 | 40.31B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
295.27 | 33.13B | 5.36B | 287.73M | 924.18M | 2.5229 |
Calidi Biotherapeutics Inc Stock (CLDI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-22-23 | Initiated | H.C. Wainwright | Buy |
| Oct-09-23 | Initiated | Robert W. Baird | Outperform |
Calidi Biotherapeutics Inc Stock (CLDI) Latest News
Calidi Biotherapeutics (CLDI) sets vote on reverse split and larger equity plan - Stock Titan
Calidi partners with TransferAI for CLD-401 regulatory filing By Investing.com - Investing.com South Africa
Calidi partners with TransferAI for CLD-401 regulatory filing - Investing.com
Calidi Biotherapeutics Announces Strategic Partnership With Transferai - TradingView
Calidi Biotherapeutics Announces Strategic Partnership with TransferAI to Drive Efficiencies in the IND Submission Process for CLD-401 Using Agentic AI - Yahoo Finance
Calidi (CLDI) Stock: Breakout Potential Analysis | Q4 2025: Better Than ExpectedVerified Stock Signals - Cổng thông tin điện tử tỉnh Lào Cai
CLDI (Calidi Biotherapeutics Inc.) posts 73.6% positive Q4 2025 EPS surprise, shares edge slightly lower in today’s trading.Revenue Diversification - Cổng thông tin điện tử tỉnh Lào Cai
Calidi Biotherapeutics Presents New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - marketscreener.com
Calidi says CLD-401 drove tumor immune response ahead of 2026 IND - Stock Titan
Calidi presents cancer therapy data at AACR meeting By Investing.com - Investing.com India
Certain Stock Options of Calidi Biotherapeutics, Inc. are subject to a Lock-Up Agreement Ending on 21-APR-2026. - marketscreener.com
Calidi (CLDI) Stock Futures Trade (Trend Weakens) 2026-04-20Price Target - Cổng thông tin điện tử tỉnh Lào Cai
Calidi presents cancer therapy data at AACR meeting - Investing.com
Calidi Biotherapeutics Presents New Data on Its Differentiated Approach to In Situ T-Cell Engagers Including a New Candidate Targeting TROP-2 at the AACR Annual Meeting in April 2026 - The Manila Times
Calidi Biotherapeutics (CLDI) seeks approval for reverse split, 1.95M-plan increase - Stock Titan
Calidi Biotherapeutics Streamlines Board, Enhances Audit Oversight - TipRanks
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor Conference to Feature Companies Advancing Clinical Pipelines and Scalable Healthcare Platforms - Sahm
Calidi Biotherapeutics to Showcase Advances in Virotherapy at RedChip's Virtual Investor Conference on April 16, 2026 - Quiver Quantitative
Calidi Biotherapeutics Announces Participation in RedChip’s April 16 Virtual Investor ... - Caledonian Record
Calidi Biotherapeutics Announces Participation in RedChip’s - GlobeNewswire
Calidi to present RedTail platform data at Iceland conference By Investing.com - Investing.com Australia
Calidi to present RedTail platform data at Iceland conference - Investing.com
Calidi Biotherapeutics Announces Speaker Presentation at IOVC Conference in Reykjavík, Iceland on April 28th Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - The Manila Times
Cancer virus therapy data from Calidi heads to Iceland conference - Stock Titan
Fed Watch: Does Calidi Biotherapeutics Inc have pricing powerFed Meeting & AI Based Buy and Sell Signals - baoquankhu1.vn
Aug Summary: How volatile is Cellectar Biosciences Inc stock2026 Spike Watch & Daily Entry Point Trade Alerts - baoquankhu1.vn
Does Calidi Biotherapeutics Inc have pricing power2026 Price Swings & Low Risk High Reward Trade Ideas - baoquankhu1.vn
Calidi Biotherapeutics (CLDI) Stock Analysis Report | Financials & Insights - Benzinga España
Are short sellers targeting Calidi (CLDI) Stock | Price at $0.26, Up 5.03%Community Risk Signals - Cổng thông tin điện tử tỉnh Lào Cai
Calidi Biotherapeutics, Inc. (CLDI) Stock Price, News, Quote & History - Yahoo! Finance Canada
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform’s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - Sahm
Aug Shorts: Is Calidi Biotherapeutics Inc forming a bullish divergenceWeekly Trend Report & Fast Entry and Exit Trade Plans - baoquankhu1.vn
Calidi Biotherapeutics Announces Speaker Presentation At ASGCT and Highlighting the Redtail Platform?s Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - marketscreener.com
Calidi Biotherapeutics Announces Speaker Presentation at ASGCT Conference in Boston on May 14, 2026 Highlighting the RedTail Platform's Ability to Deliver Genetic Medicines to Distal Sites of Disease with Systemic Therapy - Bitget
Sell Signal: Is Calidi Biotherapeutics Inc subject to activist investor interestOptions Play & Long-Term Growth Portfolio Plans - baoquankhu1.vn
Is Calidi (CLDI) Stock suitable for dividend investors | Price at $0.26, Down 0.39%Expert Verified Trades - Cổng thông tin điện tử tỉnh Lào Cai
Calidi Biotherapeutics to reduce board size as director term nears expiration By Investing.com - Investing.com Australia
Calidi Biotherapeutics to reduce board size as director term nears expiration - Investing.com Canada
Calidi Biotherapeutics (CLDI) Hinges on High-Stakes Q4 2026 IND Filing as Market Waits for Catalyst - Bitget
Allan Camaisa to Leave Calidi Board; Scott Leftwich Joins Audit Committee - TradingView
Director transition leads Calidi Biotherapeutics (CLDI) to cut board size to five - Stock Titan
Calidi Biotherapeutics to Present New Data on Its Lead Asset CLD-401 at the AACR Annual Meeting in April 2026 - The Manila Times
Calidi Biotherapeutics Inc Stock (CLDI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.67%
Cap:
|
Volume (24h):